Moya-Guzmán MJ, de Solminihac J, Padilla C, Rojas C, Pinto C, Himmel T, and Pino-Lagos K. International Journal of Molecular Sciences, 2023.
This review examines the role of small extracellular vesicles (sEVs) released by immune cells, focusing on their contribution to intercellular communication, immune regulation, pathological processes, and their potential biomedical applications. sEVs are membrane-bound vesicles, generally around 50–150 nm in size, that can transport proteins, lipids, mRNA, miRNA, DNA, and cytokines between cells. Because their molecular cargo reflects characteristics of the cells from which they originate, sEVs can profoundly alter the phenotype and function of recipient cells.
The authors organize the available evidence according to three broad groups of immune cells: cells involved in the first line of defense, antigen-presenting cells, and T-cell populations. The review emphasizes that immune-cell-derived sEVs do not have a single biological function. Depending on their cellular origin, activation state, cargo, and pathological context, they can either promote or suppress inflammation and immune responses.
Among cells of the first line of defense, neutrophil-derived vesicles have been associated with antimicrobial activity and modulation of macrophages. However, the authors emphasize that many studies on neutrophils analyze larger extracellular vesicles rather than strictly defined sEVs, illustrating one of the methodological difficulties in the field. Eosinophil-derived vesicles are particularly relevant in asthma: vesicles obtained from asthmatic patients can modify eosinophil behavior and affect epithelial and muscle cells, suggesting that they can transmit disease-associated signals to other cells. By contrast, the literature on basophil-derived sEVs remains very limited.
Mast-cell-derived sEVs contain immunologically active molecules and nucleic acids and can influence both innate and adaptive responses. Experimental studies show that these vesicles can promote lymphocyte activation, stimulate dendritic-cell maturation, transport antigens, and act as immunological adjuvants. Their cargo can also contribute to disease: for example, mast-cell-derived sEV containing miR-21 has been implicated in airway inflammation and oxidative stress in experimental asthma.
A particularly promising biomedical application involves natural killer (NK) cell-derived sEVs. These vesicles contain cytotoxic molecules such as perforin, FasL, granzyme A, and granzyme B and can kill tumor cells. Experimental studies have demonstrated activity against hematological malignancies and melanoma, including inhibition of tumor growth in a murine melanoma model without detectable adverse effects on healthy cells. Consequently, NK-cell-derived sEVs are being investigated as potential cell-free anti-cancer agents. The diagram on page 5 summarizes these functions alongside those of neutrophils, eosinophils, basophils, and mast cells.
The review also highlights the importance of sEVs released by antigen-presenting cells. Dendritic-cell-derived sEVs can contain functional MHC-I, MHC-II and co-stimulatory molecules and therefore participate in antigen presentation and T-cell activation. Early experimental work demonstrated that tumor-antigen-loaded dendritic-cell sEVs could retard tumor growth in mice. Their ability to transfer peptide–MHC complexes and miRNAs between cells suggests that sEVs can amplify or modify adaptive immune responses without requiring direct contact between the original immune cells and their targets.
Macrophage-derived sEVs illustrate especially well the context-dependent nature of extracellular-vesicle activity. Vesicles from pro-inflammatory and anti-inflammatory macrophages carry different molecular cargo and can promote inflammation, fibrosis, tumor migration, or tissue injury, but they can also contribute to tissue repair and suppression of inflammatory responses. The review discusses experimental applications ranging from myocardial repair and inflammatory pain to the delivery of therapeutic enzymes across biological barriers. ijms-2023-08 ijms-2023-08
Similarly, myeloid-derived suppressor cell (MDSC)-derived sEVs generally retain the immunoregulatory properties of their cells of origin. In cancer, they can promote tumor progression, angiogenesis and the polarization of macrophages toward a pro-tumoral phenotype. In inflammatory and autoimmune conditions, however, the same general suppressive capacity can become therapeutically advantageous. Experimental administration of MDSC-derived sEVs has reduced disease manifestations in models of colitis, arthritis, alopecia, autoimmune hepatitis and Sjögren’s syndrome.
B-cell-derived sEVs participate in antigen presentation, B-cell maturation and immune communication. They can carry functional B-cell receptors and MHC molecules, while their circulating abundance and molecular composition may also provide clinically useful information. For example, CD19+ sEVs expressing CD39 and CD73 can generate immunosuppressive adenosine and impair CD8+ T-cell responses following chemotherapy. Changes in circulating B-cell-derived sEVs have also been proposed as indicators of humoral immune activity and antibody-mediated rejection following kidney transplantation.
The T-cell compartment further demonstrates the functional diversity of sEVs. CD8+ T-cell-derived sEVs can contain perforin and granzymes and exert direct cytotoxic effects, including anti-tumor activity. At the same time, CD73 carried by these vesicles can generate adenosine and suppress T-cell activation, demonstrating that vesicles from the same broad cell lineage may mediate either effector or regulatory functions depending on their molecular composition and context.
CD4+ T-cell-derived sEVs can likewise modify immune and non-immune cells. They have been shown experimentally to inhibit T-cell proliferation and CD8+ cytotoxicity, while in other settings they can promote inflammatory processes associated with atherosclerosis and cardiac damage. Their abundance may also have biomarker potential, as increased circulating CD4+ T-cell-derived sEVs have been reported in active chronic hepatitis C compared with other chronic liver diseases.
Particular attention is given to regulatory T cells (Tregs). Treg-derived sEVs reproduce important aspects of their parent cells’ immunosuppressive function. They can inhibit CD4+ T-cell proliferation and IFN-γ secretion through mechanisms involving molecules such as CD73 and the transfer of regulatory miRNAs. The review also describes evidence that Neuropilin-1 carried by Treg-derived sEVs contributes to immune tolerance in transplantation models. Experimental sEVs generated from induced Tregs have additionally reduced inflammatory responses in a mouse model of arthritis, supporting their potential use as cell-free immunoregulatory therapies.
Evidence regarding T follicular helper (Tfh) cell-derived sEVs remains much more limited. Nevertheless, circulating CD4+CXCR5+ vesicles have been identified in kidney-transplant recipients, and vesicles from patients experiencing antibody-mediated rejection can stimulate B cells and plasma cells in vitro. These observations suggest that Tfh-derived sEVs may participate in Tfh–B-cell communication and potentially serve as indicators or mediators of transplant rejection.
Overall significance
The central message of the review is that small extracellular vesicles constitute an important extension of immune-cell function. Rather than being passive cellular products, they operate as molecular communication systems capable of transferring complex biological information between cells. Importantly, their effects often resemble the functional phenotype of their cells of origin: cytotoxic cells can produce cytotoxic vesicles, whereas regulatory cells can produce immunosuppressive vesicles. At the same time, their biological effects are strongly dependent on cellular activation and disease context.
This versatility creates substantial biomedical potential. Immune-cell-derived sEVs could theoretically be exploited to enhance inflammation and anti-tumor immunity in cancer or suppress excessive inflammation in autoimmune and inflammatory diseases. They may also serve as biomarkers of disease activity, therapeutic-response indicators, antigen-delivery systems, or vehicles for therapeutic molecules. One potential advantage over cell-based therapy is that vesicles should not undergo the phenotypic changes or cellular plasticity that living therapeutic cells may experience after administration.
However, the review makes clear that translation into clinical practice still faces important challenges. These include obtaining sufficient quantities of standardized sEVs for individual patients, improving their isolation and characterization, determining appropriate therapeutic doses, and developing strategies capable of directing vesicles efficiently toward specific cells or tissues. Much of the evidence reviewed is also derived from in vitro experiments and animal models rather than established clinical therapies.
In conclusion, the paper presents immune-cell-derived sEVs as versatile mediators of immunity with significant diagnostic and therapeutic potential. Their capacity to reproduce selected functions of their parent cells while transporting proteins, lipids and genetic material makes them particularly attractive for cell-free immunotherapy. The evidence reviewed supports applications ranging from cancer treatment and immune suppression to transplantation, inflammatory disease and biomarker development, but further basic and clinical research is required to standardize their production, understand their targeting and establish their safety and therapeutic efficacy in humans.